An Open Label Single-Dose Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104.
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Avibactam (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- 04 Jan 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 10 Oct 2011 New trial record